Emerge Health

Neonatology /
Paediatrics

committed to neonatology
today, tomorrow and in the future

neonatal
Emerge Health’s specialisation extends into neonatology, working alongside the medical community to improve the level of care for preterm babies. Thanks to our life saving products like Curosurf our approach and the important relationships in this field, Emerge has become a partner for neonatologists.

Rare Diseases

RDS (Respiratory Distress Syndrome)

Neonatal respiratory distress syndrome is a typical condition in preterm infants. Rather than identifying a single pathology, RDS is usually used to identify a complex clinical picture whose symptoms are due to an under-development of the respiratory system. Severity and incidence of this pathology are directly linked with the degree of prematurity, with infants born before the 28th week of gestation being at greater risk.
Respiratory failure in preterm infants with RDS is due to a shortage in the pool of pulmonary surfactant, which helps to create a biofilm covering the inner walls of the alveoli. The physiological role of surfactant is to allow the lungs to expand and avoid collapse (atelectasis) during the expiratory phases. Lack of surfactant results in difficulty in breathing, with low oxygenation, increased breathing effort and the need for respiratory support.
The pool of available surfactant in a preterm infant is usually extremely limited compared to that of a term neonate and further decreases as a result of RDS. When necessary, the administration of exogenous surfactant can alleviate the symptoms of this syndrome by supplementing the endogenous pool of surfactant, thereby enabling the biofilm to be replenished.

Patent Ductus Arteriosus (PDA)

In a developing foetus, the ductus arteriosus (DA) is a vessel connecting the pulmonary artery to the aortic arch. It allows the blood from the right ventricle to bypass the lungs.
In normal newborns, the DA is closed within a few hours after birth. In preterm babies this blood vessel sometimes remains open meaning that the pressure gradient blood flows back from the aorta to the pulmonary artery. This condition is called patent ductus arteriosus (PDA) and affects the perfusion of the lungs and other organs including the brain, kidney, and mesentery (tissue that attaches organs to the body wall).

Products

Curosurf®

Curosurf® intratracheal suspension is a natural surfactant prepared from porcine lungs. It is administered via the intra-tracheal route in intubated infants undergoing mechanical ventilation for respiratory distress syndrome (RDS).
Curosurf® is indicated in preterm infants for the treatment of respiratory distress syndrome, or for the prophylaxis in neonates at high risk of developing RDS or with evidence of surfactant deficiency. It is advisable to commence the treatment as soon as possible after diagnosing RDS.

Curosurf®is administered via the endotracheal tube, either as a single bolus directly into the lower trachea, or as two aliquots, one for each of the primary bronchi. Curosurf® should only be administered by those trained and experienced in the care and resuscitation of preterm infants.

For more information click here

PDA Treatment (patent ductus arteriosus)

Emerge Health has access to medicines indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age. For more information click here


For information on this product specific to Australian healthcare professionals, including clinical and therapy resources, please visit  neonatal.emergehealth.com.au

Want access to our healthcare professional resources?

Register Now
This medical information is intended only for healthcare professionals in Australia. The products discussed herein may have different product labelling in other countries.
The information within this site is intended to provide balanced, scientific, and evidence based answers to unsolicited medical questions. This resource may discuss regimens that have not been approved by Australia's Therapeutic Goods Administration. For full Product Information including indications, contraindications, warnings, precautions, and adverse events, please see the appropriate product labelling. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional licence, experience and knowledge of the patient.